The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 ...

Canada has detected its first presumptive case of H5 bird flu in a person, a teenager in the western province of British ...

In a media briefing streamed live on Canada's Global News, Bonnie Henry, MD, BC's health officer, shared the latest investigation ... (Schnirring, 11/12) Novavax yesterday announced that the US Food ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late.Health officials say it's important to get ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. (Washington Post) Air purifiers in ...

and Novavax says additional data – including on manufacturing – will be submitted in the second quarter. A US trial is also ongoing and should read out in a few weeks. UK Health Secretary Matt ...

Antibiotic-Resistant Bacteria Could Pose Major Health Threat Across Asia Nov. 7 ... Nov. 6, 2024 — By analyzing all live births in Canada over a six-year period and following children for ...

Novavax’s COVID-19 vaccine produced higher ... There are 26 potential vaccine candidates in clinical trials, according to the World Health Organization’s reckoning, with the most advanced ...